Skullcandy's (SKUL) Higher-Than-Expected Gross Margin Offset Low Revenue; Roth Capital Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jefferies Downgrades Skullcandy (SKUL) to Hold
November 6, 2015 7:20 AM ESTJefferies downgraded Skullcandy (NASDAQ: SKUL) from Buy to Hold with a price target of $5.00 (from $17.00) on reduced visibility following Q3 results.
Analyst Randal Konik commented, "We are lowering our rating on SKUL to Hold, as the company issued a weak 4Q... More
After-Hours Movers 11/05: (DATA) (WTW) (QRVO) Higher; (KBIO) (MW) (GLUU) Lower (more...)
November 5, 2015 6:17 PM ESTKaloBios Pharma (NASDAQ: KBIO) 32.6% LOWER; announced that it will reduce its workforce as part of a plan to reduce operating costs. This action will reduce the company's workforce by approximately 17 employees (or 61%), and will focus the company's resources on the ongoing development of lenzilumab, also known as KB003, in chronic monomyelocytic leukemia (CMML), while it continues to pursue strategic alternatives for the company.
The Men's Wearhouse (NYSE: MW) 28% LOWER; the Company now expects adjusted EPS to be in the... More
Skullcandy (SKUL) Reports In-Line Q3 EPS
November 5, 2015 4:05 PM ESTSkullcandy (NASDAQ: SKUL) reported Q3 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $67.2 million versus the consensus estimate of $68.55 million.
Skullcandy sees FY2015 EPS of $0.37-$0.39, versus the consensus of $0.41.
For earnings history and earnings-related data on Skullcandy (SKUL) click here.
... MoreTrading Radar for 11/5: Disney (DIS), Celgene (CELG), SeaWorld (SEAS), Sprouts (SFM), CyberArk (CYBR) Report
November 4, 2015 3:11 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
A.M. Castle & Co. (NYSE: CAS) - no Street consensus
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus EPS $0.11
AES Corp (NYSE: AES) - consensus EPS $0.38
ANSYS... More
